NOD2 and colitis: Considering that (i) the NOD2‐RIPK2 signalling is protective in IBD,30, 31, 35 (ii) MDP treatment activates the NOD2‐RIPK2 signalling and protects mice from experimental colitis,32, 36, 37 and (iii) we previously found OTUB2 enhanced NOD2 signalling by stabilising RIPK2, we next addressed the significance of OTUB2 in NOD2 signalling in vivo by investigating the effect of MDP treatment on experimental colitis in Otub2+/+ and Otub2–/– mice.